Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …

In addition to gene correction therapy and cell transplantation techniques, multidisciplinary
approaches to drug discovery and development offer promising therapeutic strategies for …

In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …

Genetic deletion of Myostatin, a member of the Transforming Growth Factor-beta family of
signalling molecules, resulted in excessive growth of skeletal muscle. It demonstrated the …

Myostatin is an endogenous, negative regulator of muscle growth determining both muscle
fiber number and size. The myostatin pathway is conserved across diverse species ranging …

Myostatin is a negative regulator of muscle mass. Important advances in our understanding
of the complex biology of this factor have revealed the therapeutic potential of antagonizing …

Background Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass
in a variety of disorders, including the muscular dystrophies, cachexia, and sarcopenia …

Increasing the size and strength of muscles represents a promising therapeutic strategy for
musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of …

Inhibition of myostatin signalling or its biological activity has recently emerged as a potential
remedial approach against muscle wasting and degenerative diseases such as muscular …

Myostatin is a secreted protein that negatively regulates skeletal muscle mass determining
both muscle fiber number and size. The myostatin pathway is conserved and regulates …